Yiwen Mo
Sun Yat-sen University(CN)Sun Yat-sen University Cancer Center(CN)
Publications by Year
Research Areas
Lung Cancer Diagnosis and Treatment, Medical Imaging Techniques and Applications, Radiomics and Machine Learning in Medical Imaging, Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes(2022)39 cited
- → Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients(2023)20 cited
- → M1 stage subdivisions based on 18F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma(2022)10 cited
- → Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer Center(2024)9 cited
- → Repeated dynamic [18F]FDG PET/CT imaging using a high-sensitivity PET/CT scanner for assessing non-small cell lung cancer patients undergoing induction immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and consolidative immunotherapy: report from a prospective observational study (GASTO-1067)(2024)6 cited
- → Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection(2019)5 cited
- → Value of baseline and end of chemotherapy 18F-FDG PET/CT in pediatric patients with Burkitt lymphoma(2021)4 cited
- → Clinical significance of post-chemoradiotherapy 2-[18F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study(2025)2 cited
- → The Prognostic Significance of Pontine-White Matter Score in Primary Central Nervous System Lymphoma Patients(2024)1 cited
- → A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).(2024)